Cargando…

Oxycodone hydrochloride immediate-release analgesic for managing severe pain: abuse-deterrent formulations

This paper is an expert opinion in response to the development of abuse-deterrent immediate-release tablets containing oxycodone HCl. There is a potential impact, both positive and negative, of this type of dosage form on patients, those suffering from the disease of addiction, health care providers...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kibbe, AH, Franko, TS, Shah, VM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Expert Opinion
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933465/ https://www.ncbi.nlm.nih.gov/pubmed/29750036 http://dx.doi.org/10.2147/TCRM.S144564

Ejemplares similares

Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study
por: Webster, Lynn R., et al.
Publicado: (2019)

Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone
por: Markman, John, et al.
Publicado: (2018)

Oxycodone DETERx(®): A Novel Abuse-Deterrent, Extended-Release Analgesic Option for the Treatment of Patients with Chronic Pain
por: Gudin, Jeff
Publicado: (2016)

Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation†
por: Sessler, Nelson E, et al.
Publicado: (2014)

Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product
por: Pergolizzi, Joseph V, et al.
Publicado: (2018)

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation
por: Webster, Lynn R, et al.
Publicado: (2019)

Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics
por: Coplan, Paul M, et al.
Publicado: (2013)

Multimodal approaches and tailored therapies for pain management: the trolley analgesic model
por: Cuomo, Arturo, et al.
Publicado: (2019)

Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder
por: Liu, Feng, et al.
Publicado: (2006)

Comparative in vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations
por: Fujii, Akira, et al.
Publicado: (2009)

Oxycodone/Naloxone: Role in Chronic Pain Management, Opioid-Induced Constipation, and Abuse Deterrence
por: DePriest, Anne Z., et al.
Publicado: (2014)

In response to Gudin et al. — Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties
por: Crudele, Nancy T., et al.
Publicado: (2017)

Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures
por: Ulloa, Carol M, et al.
Publicado: (2009)

The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain
por: Pergolizzi, Joseph V., et al.
Publicado: (2015)

A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone
por: Webster, Lynn R., et al.
Publicado: (2016)

The unsolved case of “bone-impairing analgesics”: the endocrine effects of opioids on bone metabolism
por: Coluzzi, Flaminia, et al.
Publicado: (2015)

Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States
por: Iwanicki, Janetta L., et al.
Publicado: (2016)

Dancing with Deterrents: Understanding the Role of Abuse‐Deterrent Opioid Formulations and Naloxone in Managing Cancer Pain
por: Mitchell, Megan T.
Publicado: (2019)

Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users
por: Harris, Stephen C, et al.
Publicado: (2014)

Validity testing of patient objections to acceptance of tamper-resistant opioid formulations
por: Argoff, Charles E, et al.
Publicado: (2013)

Polycomponent mesotherapy formulations for the treatment of skin aging and improvement of skin quality
por: Prikhnenko, Sergey
Publicado: (2015)

Novel formulations of docetaxel, paclitaxel and doxorubicin in the management of metastatic breast cancer
por: Rajappa, Senthil, et al.
Publicado: (2018)

Zolpidem modified-release in insomnia
por: Kirkwood, Cynthia, et al.
Publicado: (2007)

Response to Crudele et al. Commentary on Gudin et al. “Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties”
por: Gudin, Jeff, et al.
Publicado: (2017)

Carbamazepine extended-release capsules in bipolar disorder
por: Weisler, Richard H
Publicado: (2006)

A randomized, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients
por: Inoue, Satoshi, et al.
Publicado: (2018)

The management of schizophrenia: focus on extended-release quetiapine fumarate
por: Peuskens, Joseph
Publicado: (2011)

Management of obsessive-compulsive disorder with fluvoxamine extended release
por: Ordacgi, Lídia, et al.
Publicado: (2009)

Healthcare Resource Use and Cost: The Impact of Adopting an Abuse-Deterrent Formulation of Extended Release Morphine
por: Rossiter, Louis F, et al.
Publicado: (2020)

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
por: Turkoz, Ibrahim, et al.
Publicado: (2008)

Extended-release divalproex in bipolar and other psychiatric disorders: A comprehensive review
por: Stoner, Steven C, et al.
Publicado: (2007)

Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users
por: Setnik, Beatrice, et al.
Publicado: (2017)

Can abuse deterrent formulations make a difference? Expectation and speculation
por: Budman, Simon H, et al.
Publicado: (2009)

Mitigation of IV Abuse Through the Use of Abuse‐Deterrent Opioid Formulations: An Overview of Current Technologies
por: Rauck, Richard L.
Publicado: (2019)

Interventional Spine and Pain Procedure Credentialing: Guidelines from the American Society of Pain & Neuroscience
por: Naidu, Ramana K, et al.
Publicado: (2021)

Role of Oxycodone Hydrochloride in Treating Radiotherapy-Related Pain
por: Wang, Yinxia, et al.
Publicado: (2020)

Pramipexole and its Extended Release Formulation for Parkinson’s Disease
por: Fishman, Paul S.
Publicado: (2011)

Puerpera with back pain and intermittent fever
por: Pinz, Carina, et al.
Publicado: (2018)

Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Darwish, Mona, et al.
Publicado: (2017)

Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Bond, Mary, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vi6s6qmvap2erdph8nglka75vp